FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.
What happened
FDA inspected the All India Institute of Medical Sciences in Bhubaneswar, Odisha, India, from March 17 to March 20, 2025, reviewing Dr. Mishra's conduct of a bioequivalence study of doxorubicin hydrochloride liposome injection 20 mg/10 mL run for Qilu Pharmaceutical (Hainan) Co., Ltd. FDA found that all three enrolled subjects were given Aprecap (aprepitant), a moderate CYP3A4 inhibitor that the study protocol prohibited because it affects how the study drug is processed in the body. FDA also found the informed consent form told subjects the study drug was already approved and shown to be effective, without saying whether that applied to the test or the reference product.
What FDA found
All three subjects received Aprecap (aprepitant), a CYP3A4 inhibitor the protocol banned during the study, and the investigator said this was the oncology department's usual practice before chemotherapy.
21 CFR 312.60The consent form stated that the study drug was already approved and that there was evidence it was effective in the subject's disease, which could lead people to mistaken conclusions about the investigational product.
21 CFR 50.20The consent form never made clear whether the approval and effectiveness statements referred to the test product or the reference product.
21 CFR 50.20
What FDA wants
Within 15 business days of receiving the letter, notify FDA in writing of the actions taken to prevent similar violations in the future, or explain with supporting information why you believe you complied.
Who should pay attention
- sponsors and contract research organizations running bioequivalence trials at this site
- clinical investigators who sign off on sponsor-written consent forms
- sites enrolling cancer patients in drug studies
This is a summary. Read the original letter on fda.gov.